IRIDEX Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

IRIDEX şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

0.03%

Geri Alım Getirisi

Toplam Hissedar Getirisi	0.03%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive

Jun 11

Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Aug 12

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Apr 14

We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Oct 12

Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?

Feb 25

Iridex To Benefit From New Revolutionary Glaucoma Treatment

Jan 11

Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long

Jan 03

IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines

Dec 23

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: IRIX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: IRIX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

IRIDEX Piyasaya Karşı Temettü Getirisi

IRIX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (IRIX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (IRIX) (3 yıla kadar)	n/a

Önemli Temettü: IRIX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, IRIX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: IRIX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: IRIX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

IRIDEX Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Iridex Corporation Comments on Changing Glaucoma Reimbursement Landscape

IRIDEX Corporation Announces Board and Committee Changes

IRIDEX Corporation to Report Q3, 2024 Results on Nov 12, 2024

Iridex Corporation Announces Chief Executive Officer Changes

IRIDEX Corporation announced that it expects to receive $5 million in funding from The Lind Partners, LLC

IRIDEX Corporation announced that it expects to receive $5 million in funding from The Lind Partners, LLC

IRIDEX Corporation to Report Q2, 2024 Results on Aug 08, 2024

IRIDEX Begins the Process to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

IRIDEX Begins the Process to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

IRIDEX Corporation Announces Composition of Audit Committee

Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive

IRIDEX Corporation Appoints Patrick Mercer as Its President

Consensus EPS estimates fall by 32%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth?

IRIDEX Corporation to Report Q1, 2024 Results on May 14, 2024

IRIDEX Corporation, Annual General Meeting, Jun 18, 2024

Iridex's Strategic Review Process Should Bear Fruit 'Soon'

Full year 2023 earnings: EPS and revenues miss analyst expectations

IRIDEX Corporation to Report Q4, 2023 Results on Mar 26, 2024

Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues

Price target decreased by 48% to US$2.00

Iridex Corporation Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Iridex Corporation Launches New Iridex 532 and Iridex 577 Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

IRIDEX Corporation announced delayed 10-Q filing

IRIDEX Corporation announced delayed 10-Q filing

New major risk - Share price stability

IRIDEX Corporation to Report Q3, 2023 Results on Nov 14, 2023

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Consensus EPS estimates fall by 35%

New minor risk - Share price stability

Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Year 2023

IRIDEX Corporation to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings: EPS misses analyst expectations

IRIDEX Corporation Reiterates Financial Guidance for 2023

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Price target decreased to US$5.63

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Year 2022

IRIDEX Corporation to Report Q3, 2022 Results on Nov 10, 2022

We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Iridex Corporation Showcases its Non-Incisional Treatments for Glaucoma and Introduces Sweep Management Software at AAO 2022

IRIDEX Corporation Revises Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

IRIDEX Corporation to Report Q2, 2022 Results on Aug 15, 2022

IRIDEX Corporation Obtains Regulatory Clearance for Cyclo G6(R) Glaucoma Platform in China

IRIDEX Corporation Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$9.75

Iridex Corporation Modifies the Composition of its Audit Committee, Compensation Committee, and Nominating and Governance Committee

Consensus EPS estimates fall by 62%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IRIDEX Corporation to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.089 (vs US$0.20 loss in 2Q 2020)

Iridex Corporation Revises Earnings Guidance for the Year 2021

No longer forecast to breakeven

Price target increased to US$10.50

IRIDEX Corporation Provides Earnings Guidance for the Fiscal Year 2021

Iridex Corporation Announces It Cannot Provide Meaningful Financial Guidance for 2021

IRIDEX Corporation announced that it has received $10 million in funding from Topcon America Corporation

IRIDEX Corporation to Report Q4, 2020 Results on Mar 22, 2021

IRIDEX Corporation (NasdaqGM:IRIX) entered into an asset purchase agreement to acquire substantially all the assets from Topcon Medical Laser Systems Inc.

Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?

New 90-day high: US$5.82

Price target raised to US$6.50

New 90-day high: US$4.13

Iridex To Benefit From New Revolutionary Glaucoma Treatment